Reprogramming Tumor Blood Vessels for Enhancing Immunotherapy

Martina Schmittnaegel; Michele De Palma

doi:10.1016/j.trecan.2017.10.002

Reprogramming Tumor Blood Vessels for Enhancing Immunotherapy

Trends Cancer. 2017 Dec;3(12):809-812. doi: 10.1016/j.trecan.2017.10.002. Epub 2017 Oct 27.

Authors

Martina Schmittnaegel¹, Michele De Palma²

Affiliations

¹ The Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland.
² The Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland. Electronic address: michele.depalma@epfl.ch.

PMID: 29198436
DOI: 10.1016/j.trecan.2017.10.002

Abstract

Angiogenic blood vessels contribute to generating an immunosuppressive tumor microenvironment, in part by limiting the extravasation of T cells. Functional reprogramming of angiogenic blood vessels, for example through angiopoietin-2 blockade, may improve T cell trafficking in tumors and the efficacy of immune checkpoint blockade (ICB) and other cancer immunotherapies.

Publication types

Review

MeSH terms

Angiopoietin-2 / antagonists & inhibitors
Angiopoietin-2 / genetics
Angiopoietin-2 / immunology
Blood Vessels / growth & development
Blood Vessels / immunology*
Blood Vessels / pathology
Cellular Reprogramming / genetics
Cellular Reprogramming / immunology
Humans
Immunosuppression Therapy / methods
Immunotherapy / methods
Neoplasms / immunology*
Neoplasms / therapy
T-Lymphocytes / immunology*
T-Lymphocytes / pathology
Tumor Microenvironment / immunology*

Substances

Angiopoietin-2